Table 1.
Clinical characteristics of the study cohort
| Variable | Category | GNET Type 1 | GNEN G3 | Controls |
|---|---|---|---|---|
| Number | No. | 42 | 4 | 63 |
| Gender | Males | 10 | 3 | 20 |
| Females | 32 | 1 | 43 | |
| Age | Mean (range) | 55 (28–87) | 55 (40–84) | 44 (23–78) |
| Age at initial diagnosis | Mean (range) | 53 (27–81) | 51 (38–83) | N/A |
| Follow-up since initial diagnosis (years) | Mean (range) | 2.6 (0.12–14.7) | 3.8 (0.5–10.5) | N/A |
| Grade | Grade 1 | 32 | – | N/A |
| Grade 2 | 10 | – | ||
| Grade 3 NET | – | 1 | ||
| NEC | – | 3 | ||
| Ki-67 (%) | Mean (range) | 2.5 (1–17) | 51 (30–75) | N/A |
| Active Chronic Atrophic Gastritis | % (N) | 81% (34) | N/A | N/A |
| Gastrin Levels [N ≤ 115 pg/ml] | % Elevated | 75%a | 25%b | N/A |
| Mean FC (range) | 4.2 (0.12–13.3) | 0.57 (0.1–1.04) | ||
| Mean Value (range) | 483 (18–1525) | 66 (12–120) | ||
| Intestinal Metaplasia | No. | 31 | 0 | N/A |
| Proton pump inhibitor treatment | % On treatment | 7% | 25% | |
| Chromogranin A [N < 100μg/l] | % Elevated | 44% | 25% | N/A |
| Mean (range) | 142 (20–700) | 203 (20–700) | ||
| Disease extent by imaging and histology | Image-positive & R1 | 15 | 1 | N/A |
| Image-negative & R0 | 18 | 3 | ||
| Image-negative & R1 | 9 | – | ||
| Current treatment | Type | No (Surveillance) | No (Surveillance) | N/A |
| Previous treatments | None | 0 | 1 | N/A |
| Polypectomy | 24 | 0 | ||
| Partial gastrectomy | 7 | 1 | ||
| Total gastrectomy | 3 | 2 |
N: within normal range; No.: number of cases; N/A: Not applicable; FC: Fold change; a 2 subjects on PPI; b hypergastrinemia on PPI; R – resection/polypectomy margin; Chromogranin A assay: ELISA (Tecan Sunrise, Austria); Gastrin Levels [N ≤ 115 pg/ml]